These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 30359685)

  • 1. Nanoamorphous drug products - Design and development.
    Jog R; Burgess DJ
    Int J Pharm; 2018 Dec; 553(1-2):238-260. PubMed ID: 30359685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formulation design and evaluation of amorphous ABT-102 nanoparticles.
    Jog R; Kumar S; Shen J; Jugade N; Tan DC; Gokhale R; Burgess DJ
    Int J Pharm; 2016 Feb; 498(1-2):153-69. PubMed ID: 26705150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of an amorphous nanosuspension by sonoprecipitation-formulation and process optimization using design of experiment methodology.
    Gajera BY; Shah DA; Dave RH
    Int J Pharm; 2019 Mar; 559():348-359. PubMed ID: 30721724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controlled antisolvent precipitation of spironolactone nanoparticles by impingement mixing.
    Dong Y; Ng WK; Shen S; Kim S; Tan RB
    Int J Pharm; 2011 May; 410(1-2):175-9. PubMed ID: 21397674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amorphous solid dispersion of nisoldipine by solvent evaporation technique: preparation, characterization, in vitro, in vivo evaluation, and scale up feasibility study.
    Chavan RB; Lodagekar A; Yadav B; Shastri NR
    Drug Deliv Transl Res; 2020 Aug; 10(4):903-918. PubMed ID: 32378174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.
    Nielsen LH; Gordon S; Holm R; Selen A; Rades T; Müllertz A
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):942-51. PubMed ID: 24075980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A continuous and highly effective static mixing process for antisolvent precipitation of nanoparticles of poorly water-soluble drugs.
    Dong Y; Ng WK; Hu J; Shen S; Tan RB
    Int J Pharm; 2010 Feb; 386(1-2):256-61. PubMed ID: 19922777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive quality by design approach for stable nanocrystalline drug products.
    Jog R; Burgess DJ
    Int J Pharm; 2019 Jun; 564():426-460. PubMed ID: 31026489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preparation and characterization of spironolactone-loaded nanocapsules for paediatric use.
    Limayem Blouza I; Charcosset C; Sfar S; Fessi H
    Int J Pharm; 2006 Nov; 325(1-2):124-31. PubMed ID: 16872764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preparation and characterization of spironolactone nanoparticles by antisolvent precipitation.
    Dong Y; Ng WK; Shen S; Kim S; Tan RB
    Int J Pharm; 2009 Jun; 375(1-2):84-8. PubMed ID: 19481693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hybridized nanoamorphous micellar dispersion using a QbD-DM
    Rathod V; Stagner WC; Gajera B; Haware RV
    Int J Pharm; 2020 Oct; 588():119727. PubMed ID: 32758594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality by Design approach to spray drying processing of crystalline nanosuspensions.
    Kumar S; Gokhale R; Burgess DJ
    Int J Pharm; 2014 Apr; 464(1-2):234-42. PubMed ID: 24412337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparation and Characterization of Stable Nanosuspension for Dissolution Rate Enhancement of Furosemide: A Quality by Design (QbD) Approach.
    Marzan AL; Tabassum R; Jahan B; Asif MH; Reza HM; Kazi M; Alshehri SM; de Matas M; Shariare MH
    Curr Drug Deliv; 2018; 15(5):672-685. PubMed ID: 29359667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of Spray-Dried Dispersions in Early Pharmaceutical Development: Theoretical and Practical Challenges.
    Li J; Patel D; Wang G
    AAPS J; 2017 Mar; 19(2):321-333. PubMed ID: 27896684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nano-amorphous spray dried powder to improve oral bioavailability of itraconazole.
    Kumar S; Shen J; Burgess DJ
    J Control Release; 2014 Oct; 192():95-102. PubMed ID: 25009979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spray drying ternary amorphous solid dispersions of ibuprofen - An investigation into critical formulation and processing parameters.
    Ziaee A; Albadarin AB; Padrela L; Faucher A; O'Reilly E; Walker G
    Eur J Pharm Biopharm; 2017 Nov; 120():43-51. PubMed ID: 28822874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Factors of Importance for Spray Drying of Small Interfering RNA-Loaded Lipidoid-Polymer Hybrid Nanoparticles for Inhalation.
    Dormenval C; Lokras A; Cano-Garcia G; Wadhwa A; Thanki K; Rose F; Thakur A; Franzyk H; Foged C
    Pharm Res; 2019 Aug; 36(10):142. PubMed ID: 31376020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and Optimisation of Spironolactone Nanoparticles for Enhanced Dissolution Rates and Stability.
    Kelidari HR; Saeedi M; Akbari J; Morteza-Semnani K; Valizadeh H; Maniruzzaman M; Farmoudeh A; Nokhodchi A
    AAPS PharmSciTech; 2017 Jul; 18(5):1469-1474. PubMed ID: 27834054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of Phase Separation Propensity for Amorphous Spray Dried Dispersions.
    McNamara D; Yin S; Pan D; Crull G; Timmins P; Vig B
    Mol Pharm; 2017 Feb; 14(2):377-385. PubMed ID: 28068097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formulation parameters of crystalline nanosuspensions on spray drying processing: a DoE approach.
    Kumar S; Xu X; Gokhale R; Burgess DJ
    Int J Pharm; 2014 Apr; 464(1-2):34-45. PubMed ID: 24447788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.